This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barbut, F.
Right arrow Articles by Petit, J.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barbut, F.
Right arrow Articles by Petit, J.-C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 1999, p. 2607-2611, Vol. 43, No. 11
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Antimicrobial Susceptibilities and Serogroups of Clinical Strains of Clostridium difficile Isolated in France in 1991 and 1997

Frédéric Barbut,1,* Dominique Decré,1 Béatrice Burghoffer,1 Danièle Lesage,1 Françoise Delisle,1 Valérie Lalande,1 Michel Delmée,2 Véronique Avesani,2 Nassita Sano,1 Cyril Coudert,1 and Jean-Claude Petit1

Department of Microbiology, Centre Hospitalier Universitaire Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Université Paris VI, Paris 12, France,1 and Department of Microbiology, University of Louvain, Brussels, Belgium2

Received 7 December 1998/Returned for modification 24 March 1999/Accepted 18 August 1999

Glycopeptides (vancomycin and teicoplanin) and metronidazole are the drugs of choice for the treatment of Clostridium difficile infections, but trends in susceptibility patterns have not been assessed in the past few years. The objective was to study the MICs of glycopeptides and metronidazole for unrelated C. difficile strains isolated in 1991 (n = 100) and in 1997 (n = 98) by the agar macrodilution, the E-test, and the disk diffusion methods. Strain susceptibilities to erythromycin, clindamycin, tetracycline, rifampin, and chloramphenicol were also determined by the ATB ANA gallery (bioMérieux, La Balme-les-Grottes, France). The MICs at which 50% of isolates are inhibited (MIC50s) and MIC90s of glycopeptides and metronidazole remained stable between 1991 and 1997. All the strains were inhibited by concentrations that did not exceed 2 µg/ml for vancomycin and 1 µg/ml for teicoplanin. Comparison of MICs determined by the agar dilution method recommended by the National Committee for Clinical Laboratory Standards and the E test showed correlations (±2 dilutions) of 86.6, 95.9, and 99% for metronidazole, vancomycin, and teicoplanin, respectively. The E test always underestimated the MICs. Strains with decreased susceptibility to metronidazole (MICs, >= 8 µg/ml) were isolated from six patients (n = 4 in 1991 and n = 2 in 1997). These strains were also detected by the disk diffusion method (zone inhibition diameter, <= 21 mm); they belonged to nontoxigenic serogroup D (n = 5) and toxigenic serogroup H (n = 1). Decreased susceptibility to erythromycin (MICs, >= 1 µg/ml), clindamycin (MICs, >= 2 µg/ml), tetracycline (MICs, >= 8 µg/ml), rifampin (MICs, >= 4 µg/ml), and chloramphenicol (MICs, >= 16 µg/ml) was observed in 64.2, 80.3, 23.7, 22.7, and 14.6% of strains, respectively. Strains isolated in 1997 were more susceptible than those isolated in 1991, and this trend was correlated to a major change in serogroup distribution. Periodic studies are needed in order to detect changes in serogroups and the emergence of strains with decreased susceptibility to therapeutic drugs.

* Corresponding author. Mailing address: Service de Bactériologie-Virologie, Hôpital Saint-Antoine, 184, rue du Faubourg Saint-Antoine, 75 571 Paris Cedex 12, France. Phone: 33 (1) 49 28 29 10. Fax: 33 (1) 49 28 24 72. E-mail: frederic.barbut{at}sat.ap-hop-paris.fr.

Antimicrobial Agents and Chemotherapy, November 1999, p. 2607-2611, Vol. 43, No. 11
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Baines, S. D., O'Connor, R., Freeman, J., Fawley, W. N., Harmanus, C., Mastrantonio, P., Kuijper, E. J., Wilcox, M. H. (2008). Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 62: 1046-1052 [Abstract] [Full Text]  
  • Martin, H., Willey, B., Low, D. E., Staempfli, H. R., McGeer, A., Boerlin, P., Mulvey, M., Weese, J. S. (2008). Characterization of Clostridium difficile Strains Isolated from Patients in Ontario, Canada, from 2004 to 2006. J. Clin. Microbiol. 46: 2999-3004 [Abstract] [Full Text]  
  • Pelaez, T., Cercenado, E., Alcala, L., Marin, M., Martin-Lopez, A., Martinez-Alarcon, J., Catalan, P., Sanchez-Somolinos, M., Bouza, E. (2008). Metronidazole Resistance in Clostridium difficile Is Heterogeneous. J. Clin. Microbiol. 46: 3028-3032 [Abstract] [Full Text]  
  • Garey, K. W, Salazar, M., Shah, D., Rodrigue, R., DuPont, H. L (2008). Rifamycin Antibiotics for Treatment of Clostridium difficile-Associated Diarrhea. The Annals of Pharmacotherapy 42: 827-835 [Abstract] [Full Text]  
  • Odou, M.-F., Muller, C., Calvet, L., Dubreuil, L. (2007). In vitro activity against anaerobes of retapamulin, a new topical antibiotic for treatment of skin infections. J Antimicrob Chemother 59: 646-651 [Abstract] [Full Text]  
  • Surowiec, D., Kuyumjian, A. G, Wynd, M. A, Cicogna, C. E (2006). Past, Present, and Future Therapies for Clostridium difficile-Associated Disease. The Annals of Pharmacotherapy 40: 2155-2163 [Abstract] [Full Text]  
  • Noren, T., Wullt, M., Akerlund, T., Back, E., Odenholt, I., Burman, L. G. (2006). Frequent Emergence of Resistance in Clostridium difficile during Treatment of C. difficile-Associated Diarrhea with Fusidic Acid.. Antimicrob. Agents Chemother. 50: 3028-3032 [Abstract] [Full Text]  
  • Aspevall, O., Lundberg, A., Burman, L. G., Akerlund, T., Svenungsson, B. (2006). Antimicrobial Susceptibility Pattern of Clostridium difficile and Its Relation to PCR Ribotypes in a Swedish University Hospital.. Antimicrob. Agents Chemother. 50: 1890-1892 [Abstract] [Full Text]  
  • Freeman, J., Stott, J., Baines, S. D., Fawley, W. N., Wilcox, M. H. (2005). Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital. J Antimicrob Chemother 56: 988-989 [Full Text]  
  • Delmee, M., Van Broeck, J., Simon, A., Janssens, M., Avesani, V. (2005). Laboratory diagnosis of Clostridium difficile-associated diarrhoea: a plea for culture. J Med Microbiol 54: 187-191 [Abstract] [Full Text]  
  • Spigaglia, P., Mastrantonio, P. (2004). Comparative analysis of Clostridium difficile clinical isolates belonging to different genetic lineages and time periods. J Med Microbiol 53: 1129-1136 [Abstract] [Full Text]  
  • Wullt, M., Odenholt, I. (2004). A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 54: 211-216 [Abstract] [Full Text]  
  • Pinto, L. J.F., Alcides, A. P.P., Ferreira, E. O., Avelar, K. E.S., Sabra, A., Domingues, R. M.C.P., Ferreira, M. C. S. (2003). Incidence and importance of Clostridium difficile in paediatric diarrhoea in Brazil. J Med Microbiol 52: 1095-1099 [Abstract] [Full Text]  
  • Ackermann, G., Degner, A., Cohen, S. H., Silva, J. Jr, Rodloff, A. C. (2003). Prevalence and association of macrolide-lincosamide- streptogramin B (MLSB) resistance with resistance to moxifloxacin in Clostridium difficile. J Antimicrob Chemother 51: 599-603 [Abstract] [Full Text]  
  • Drummond, L. J., McCoubrey, J., Smith, D. G. E., Starr, J. M., Poxton, I. R. (2003). Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period. J Med Microbiol 52: 259-263 [Abstract] [Full Text]  
  • Gravisse, J., Barnaud, G., Hanau-Bercot, B., Raskine, L., Riahi, J., Gaillard, J. L., Sanson-Le-Pors, M. J. (2003). Clostridium difficile Brain Empyema after Prolonged Intestinal Carriage. J. Clin. Microbiol. 41: 509-511 [Abstract] [Full Text]  
  • Dridi, L., Tankovic, J., Burghoffer, B., Barbut, F., Petit, J.-C. (2002). gyrA and gyrB Mutations Are Implicated in Cross-Resistance to Ciprofloxacin and Moxifloxacin in Clostridium difficile. Antimicrob. Agents Chemother. 46: 3418-3421 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»